Manages central diabetes insipidus. ANDA 210371, held by ABHAI. Desmopressin Acetate.
As of Nov 21, 2026, ANDA 210371 (Desmopressin Acetate), held by ABHAI, was first approved by FDA on Jan 28, 2019, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 28, 2019 | Original application | Approved | None posted |
| Desmopressin Acetate0.1MG · tablet;oral | Desmopressin Acetate | Rx |
| Desmopressin Acetate0.2MG · tablet;oral | Desmopressin Acetate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters